The predictive value of the World Health Organization's Fracture Risk Assessment Tool (FRAX) was evaluated using real-world community data. A population-based cohort of 141,320 women aged 50-90 years (median age, 58 years; interquartile range, 54-67) in 2004 was extracted from the central database of a large Israeli health-care services provider and insurer. Retrospective FRAX scores were calculated using computerized health records and compared with actual incidence of major osteoporotic fractures (MOFs) during the following 10 years. Fracture proportions of 6.9% for MOFs and 2.2% for hip fractures were expected, as opposed to 13.5% and 2.9% observed. The area under the receiver operating characteristic curve (AUC) of FRAX scores calculated without the inclusion of bone mineral density (BMD) data was 0.65 (95% confidence interval: 0.65, 0.66) for MOF and 0.82 (95% confidence interval: 0.81, 0.82) for hip fracture. A total of 16,578 subjects had BMD data at the index date, and their risk estimates based solely on BMD exhibited lower predictive performance for both MOFs (AUC = 0.62 vs. 0.65; P = 0.003) and hip fractures (AUC = 0.78 vs. 0.84; P < 0.001) as compared with FRAX. FRAX scores based on electronic health records provided reasonable discrimination despite some underestimation of the absolute risk of nonhip fractures. Integration of FRAX with routine clinical systems could increase implementation in daily practice and improve risk detection, especially for patients without BMD data.
Osteoporosis is an increasingly prevalent skeletal disease, causing substantial physical disability and economic burden due to bone fractures. The most common strategy for identifying patients at high risk of fracture still relies primarily on bone mineral density (BMD) testing (1), especially among primary-care physicians. BMD testing is subsidized in Israel as part of the national health benefits package. While such routine screening improves case-finding rates, BMD alone provides only limited sensitivity (2, 3) for predicting who will experience a fracture at reasonable specificity levels.
The World Health Organization's Fracture Risk Assessment Tool (FRAX) (4) was developed to assess the probability of incurring an osteoporotic fracture within the ensuing 10 years, while accounting for the multifactorial etiology of osteoporosis. It encompasses 12 different clinical risk factors and is aimed at providing higher sensitivity than BMD alone (5).
These factors include age, sex, body mass index (weight (kg)/ height (m) 2 ), previous fracture history, parental hip fracture, smoking, prolonged use of oral glucocorticoids, rheumatoid arthritis, secondary conditions that contribute to bone loss (type 1 diabetes, hypogonadism, etc.), high alcohol consumption, and BMD (the latter is optional). The model was constructed based on 7 large cohorts (1.2 million person-years) from Europe, North America, Asia, and Australia, and was then calibrated separately to over 50 countries by adjusting each calculator for local hip fracture incidence rates (which may vary 10-fold (6, 7)), while assuming a homogeneous ratio of hip fractures to nonhip fractures (8) . A new country-specific FRAX calculator for Israel was recently constructed (9) , relying on ecological data on national hip fracture rates during the years 2012 and 2013 from all Israeli hospitals and local mortality rates.
To the best of our knowledge, the performance of this tool in Israel has not yet been evaluated. Some previous studies assessing its calibration to national data on independent external data (outside the model's derivation population) were deemed to suffer from methodological limitations, such as the use of selected populations, self-reported information on outcome and risk factors, and lack of sufficient statistical power (10) . A Canadian study (11) was generally reassuring, yet New Zealand (12) and US (13) studies found insufficient predictive power and specific shortcomings in women under 60 years of age. The authors of 2 recent systematic reviews (14, 15) recommended further research in different populations prior to widespread use.
In this study, we aimed to assess the validity of FRAX and its added value beyond BMD, using local patient-level data from the community, which is reflective of the setting in which it is likely to be used. Evaluating this newly introduced instrument in a large historical prospective study is necessary for understanding its implications and is an important step toward improving current intervention allocation strategies.
METHODS

Study setting
This study utilized the computerized database of Maccabi Healthcare Services (MHS), a large Israeli government-funded health maintenance organization (HMO) insuring and providing medical care for 2 million current members. Under the 1995 national compulsory health insurance law, every Israeli citizen is registered as a member of one of 4 nationwide HMOs and has a right to select the HMO of his/her choice, free of any preconditions or limitations stemming from age, salary, or health state, and to receive all of the services included in the government's medical services basket, within a reasonable period of time and distance from his/her home. Thanks to this setting, members of each HMO are good representatives of the entire country's citizens. MHS's central electronic medical record (EMR) database includes comprehensive data on demographic factors, diagnoses (inpatient and outpatient), laboratory tests, and procedures and complete capture of prescription medication dispensations. MHS's pharmacy database is coded according to the Anatomical Therapeutic Chemical system and is accurate for capturing both medication dispensations and details of dosage and duration (16) . Dual-energy x-ray absorptiometry scanning has been included in the national health services package since January 2000 for all women and men aged 60 years or above, as well as all women and men aged 50 years or above with a prior fragility fracture, a family history of osteoporosis, body mass index <19, use of bisphosphonates or selective estrogen receptor modulators, or use of corticoids for ≥3 months (at any age).
Study population
The study population included all female MHS members aged 50-90 years (the eligible age range) in 2004 who had at least 3 years of prior MHS membership. The index date was defined by the earliest electronically available BMD test performed before June 2006 (to allow for 10 years of follow-up).
For members with no eligible BMD test result, the index date was defined as November 1, 2004 (set according to the median index date for the patients with eligible BMD data).
Members with missing data on height or weight (5%) were excluded, as these are mandatory fields in the FRAX calculator. Only 1.4% of the subjects (n = 1,964) left MHS (for reasons other than death) before completing 10 full years of followup; they were not excluded from the analysis.
Assessment of outcome
The 2 endpoint events were incident hip (femoral neck) fracture and incident major osteoporotic fracture (MOF) during the 10-year follow up period, including fractures of the femoral neck, clinical spine, forearm, and proximal humerus, in accordance with FRAX definitions (4) (Web Table 1 , available at https://academic.oup.com/aje, depicts clinical diagnoses and procedure codes). All fractures that occurred within 6 months of a documented motor vehicle accident (7%) and all events that included multiple fracture diagnosis codes with the same date (9%) were considered more likely to be major traumarelated than osteoporotic and were thus excluded from analysis. Moreover, to avoid potential double-counting of prevalent fractures (at the index date) as incident fractures (post-index date), only different classes of fractures (categorized as hip, vertebral, or nonhip-nonvertebral) were considered as new events (20% of persons with a prior fracture sustained an incident fracture). See Web Appendix 1 for details on outcome data accuracy.
Risk profile assessment
Data on diagnosis codes, medication dispensations, and demographic factors were extracted from the EMRs to populate the clinical risk factors used in FRAX. The presence of risk factors at baseline was assessed by the last data point available on the index date, except for smoking and body mass index, for which missing baseline data were replaced by the last available status up to the end of study baseline data collection (January 2016). For patients with remaining missing data on smoking status (1.5%), we used the default value ("not a current smoker") as per the World Health Organization recommendation.
The presence of a previous fracture was defined as any MOF (in accordance with the above definition of the outcome) recorded in a patient's medical history before the index date.
Since information on parental hip fracture was not collected in the EMRs, we used family history of osteoporosis as a proxy variable, similarly to Unni et al.'s recent analysis of EMR data from the European Prospective Investigation into Cancer and Nutrition (17) and the analysis by Hippisley-Cox and Coupland (18) .
Prolonged exposure to glucocorticoids was defined by dispensations of glucocorticoid medication, as detailed in Web Table 2 .
Rheumatoid arthritis, secondary osteoporosis, and high alcohol consumption were defined using diagnoses (Web Table 2 ), similarly to the EMR study by Unni et al. (17) .
Femoral neck BMD measurements were extracted from a single chain of 7 countrywide medical centers (Assuta Medical Centers Ltd., Tel Aviv, Israel), where approximately 86% of BMD scans in MHS are performed. All BMD scans were conducted using the same standardized model of the GE Lunar Prodigy dual-energy x-ray absorptiometry scanner (GE Healthcare, Chicago, Illinois). Numerical test results were extracted from historical Portable Document Format (PDF) files using optical character recognition technology. Conversion of BMD values to T-scores was performed using reference standards for white women from the Third National Health and Nutrition Examination Survey (19) .
Osteoporosis treatment was not required by FRAX but was used for stratification of performance. It was assessed by dispensations of prescription medications (mainly bisphosphonates but also including raloxifene, strontium ranelate, denosumab, teriparatide, and calcitonin) and divided into categories of before/after the index date and less than/more than 3 cumulative years of therapy (in accordance with bisphosphonate registration trials and clinical guidelines for an initial course of treatment).
Since the formula and coefficients used in the FRAX equation are not publicly available, the scores were computed using the downloadable paper charts from the FRAX website (20) . Scores were computed for the entire study population according to the charts using body mass index, age, and the sum of clinical risk factors (without BMD). In addition, for patients with available BMD measured before June 2006, separate scores were computed according to the charts using BMD, age, and the sum of clinical risk factors. The charts provide a range of scores corresponding to each sum of clinical risk factors, as well as a midpoint. The midpoint was used for the purpose of the current study.
Lastly, we calculated the proportion of patients who exceeded a MOF score of 20% or a hip fracture score of 3%, in accordance with the FRAX-based guidelines of the National Osteoporosis Foundation (Arlington, Virginia) (21) .
Statistical analysis
The baseline characteristics of patients with and without a fracture event within 10 years were compared using analysis of variance or the Kruskal-Wallis test for normally and nonnormally distributed continuous variables and the χ 2 test for categorical variables. Standardized mean differences less than 0.1 standard deviation were considered nonsignificant. Discrimination measures the model's ability to separate persons who do and do not experience a fracture. It was assessed using the area under the receiver operating characteristic (ROC) curve (AUC) (22) .
DeLong's unpaired test (23) was used to compare ROC curves for different subpopulations (elderly vs. younger patients, patients with prolonged osteoporosis treatment vs. others, and patients with diabetes (type 1 or type 2) at the index date vs. those who were diabetes-free).
Calibration measures the agreement between the predicted fracture probabilities and the actual observed proportion of patients who sustained a fracture. FRAX calibration was assessed by 2 approaches: 1) the Hosmer-Lemeshow goodnessof-fit test comparing observed and expected outcomes over 10 risk deciles and 2) the ratio between observed and expected fracture proportions. A significant Hosmer-Lemeshow test (χ 2 statistic) indicates lack of fit (the predicted values do not tend to match the predicted frequency when split by risk deciles).
The proportion of expected MOFs/hip fractures was calculated by the sum of all individual MOF/hip FRAX scores divided by 100 (representing probabilities) and by the total number of patients.
The predictive performance of FRAX was also compared with a parsimonious model including T-score alone (or Tscore and age as continuous covariates). The model was fitted via logistic regression and trained using a randomly selected 80% of the study population (to avoid overfitting), and its performance was examined based on the remaining 20% of the population (test sample). DeLong's paired test was used to compare ROC curves on the same population (FRAX vs. T-score alone). Since the AUC may be considered as having low sensitivity for detecting improvements in model performance, we also computed the integrated discrimination improvement, which estimates the improvement in average sensitivity and average specificity (24) , and the net reclassification improvement.
All analysis was conducted using standard statistical software: SPSS, version 21 (SPSS Inc., Chicago, Illinois), and the R statistical programming language (R Foundation for Statistical Computing, Vienna, Austria) (25) .
The study protocol was approved by Assuta Hospital's institutional review board and the Tel Aviv University ethics committee.
RESULTS
Study population
A total of 141,320 female MHS members were eligible (denoted the "total population"), out of which 16,578 patients had an electronically available BMD test performed before June 2006 (denoted "population with BMD at the index date"). Median duration of continuous membership in MHS at the index date was 12 years (interquartile range (IQR), , the median age of the total population was 58 years (IQR, 54-67), and 4% of the population had a prior MOF at the index date. Overall, 10% of the total population died within 10 years of the index date, 78% without experiencing a MOF event. A total of 19% initiated any osteoporosis prescription therapy before the index date, yet only 4% completed 3 cumulative years of therapy before the index date. A total of 20% were ever treated for osteoporosis for 3 or more years (including post-index date).
Incident MOF and hip fracture events post-index date were observed for 13.5% and 2.9% of the total population, respectively. A total of 62% of MOFs were nonhip-nonvertebral, 22% were hip, and 16% were vertebral. Patients who sustained a MOF after the index date were older, more likely to have a history of prior fracture, exposed to glucocorticoids, or previously diagnosed with a disorder associated with secondary osteoporosis (Table 1 ). The same comparison carried out in the population with BMD at the index date revealed similar differences, as well as a lower baseline T-score for patients who later sustained a MOF event ( Table 2) .
Distribution of FRAX scores
The distribution of FRAX MOF and hip scores was nongaussian, with high kurtosis and skewness (a long right tail). FRAX MOF and hip scores were higher among patients with an incident MOF than among others, both in the total population (Table 1 ) and in the population with BMD data at the index date (Table 2) , albeit with considerable overlap. Table 3 shows levels of discrimination and calibration in the total population as well as in selected subgroups of interest. In the total population, using FRAX without BMD, the AUC of the FRAX score was 0.65 for MOF and 0.82 for hip fracture. The sum of FRAX scores underestimated the actual fracture incidence, with 13.5% observed MOFs versus 6.9% expected and 2.9% observed hip fractures versus 2.2% expected. Figure 1 depicts the predicted and observed fracture rates by decile of FRAX score, indicating some underestimation of observed fracture rates (Hosmer-Lemeshow test: P < 0.001 for both MOFs and hip fractures).
When comparing patients under 70 years of age at the index date with others, discrimination was better among the younger patients for hip fractures (AUC = 0.72 vs. 0.64; DeLong's P < 0.001) and similar for MOFs (AUC = 0.59 vs. 0.57; DeLong's P = 0.01). The observed/expected discrepancy was larger in the younger subgroup.
FRAX hip fracture discrimination was lower for patients treated for osteoporosis for at least 3 years (before or after the index date) as compared with treatment-naive patients or those treated for less than 3 years (AUC = 0.75 vs. 0.83; P < 0.001), but MOF discrimination did not differ. The observed/ expected discrepancy was larger in the treated subgroup. Similar findings were observed when comparing patients treated for at least 3 years before the index date (4% of the cohort) with others.
When comparing patients with diabetes and other patients, a similar level of discrimination was observed for MOFs in diabetic patients (AUC = 0.64 vs. 0.65, P = 0.12) but slightly lower discrimination for hip fractures. Diabetic patients were older than diabetes-free patients (mean age = 65 years vs. 60 years), with higher observed fracture incidence rates and a larger observed/expected discrepancy in hip fractures.
Overall, using FRAX without BMD, 16.9% of the patients met the National Osteoporosis Foundation intervention criteria, with 4.7% having a risk of 20% or more for MOFs and an additional 12.2% having a risk of 3% or more for hip fractures.
FRAX scores with BMD
In the population with BMD data on the index date, using FRAX with femoral neck BMD, the AUC of the FRAX score was 0.67 (95% confidence interval (CI): 0.66, 0.68) for MOF and 0.82 (95% CI: 0.79, 0.84) for hip fracture. A total fracture proportion of 13.6% was observed for MOFs as opposed to 7.0% expected, and the proportion of hip fractures observed was 2.0% versus 1.8% expected (Hosmer-Lemeshow test: P < 0.001).
Adjustment for spine-hip BMD discrepancies resulted in little discrimination improvement (see Web Appendix 2 for details).
Logistic regression based on T-score alone, derived using the model-training data set, yielded odds ratios (per standarddeviation decrease in T-score) of 1.94 (95% CI: 1.81, 2.08) for MOF and 3.82 (95% CI: 3.17, 4.61) for hip fracture. FRAX discrimination was better than the risk estimates based on T-score alone, with an AUC of 0.65 (95% CI: 0.62, 0.68) versus 0.62 (95% CI: 0.59, 0.64) for MOFs (DeLong's P = 0.003, continuous net reclassification improvement = 0.080, integrated discrimination improvement = 0.005) (Figure 2A ) and an AUC of 0.84 (95% CI: 0.80, 0.88) versus 0.78 (95% CI: 0.74, 0.83) for hip fractures (DeLong's P < 0.001, continuous net reclassification improvement = 0.670, integrated discrimination improvement = 0.017) ( Figure 2B ). Fracture risk estimates calculated by logistic regression combining both age and T-score yielded discrimination similar to that of FRAX and better than that of T-score alone, with AUCs of 0.65 (95% CI: 0.62, 0.68) for MOF and 0.82 (95% CI: 0.77, 0.86) for hip fracture. The number of clinical risk factors was calculated according to the FRAX paper charts using age and body mass index. c GE Lunar Prodigy dual-energy x-ray absorptiometry scanner (GE Healthcare, Chicago, Illinois).
Using FRAX with BMD data, 15.7% of the patients met the National Osteoporosis Foundation criteria, with 2.8% having a risk of 20% or more for MOFs and an additional 12.9% having a risk of 3% or more for hip fractures.
DISCUSSION
The findings of this study validated FRAX, an increasingly used World Health Organization fracture prediction tool, by utilizing the EMRs of a large population-based cohort with a high retention rate. The performance of FRAX in fracture prediction using EMRs was reasonable, especially for hip fractures, which usually pose the greatest burden. The discrimination ability of FRAX was similar to that of BMD even without requiring BMD data, which could improve detection rates for untested patients.
To our knowledge, this is the first study to have examined the performance of FRAX in Israel and the largest to have explored its applicability using EMRs. The stratification of performance by subsets of potential risk modifiers highlights areas where the risk of fracture may be suboptimally captured (due to model or data limitations). For example, somewhat lower performance was observed in our data among treated patients, although a previous study by Leslie et al. (26) suggested that prior therapy does not invalidate FRAX predictions.
Our findings indicate possible underestimation of the absolute risk of nonhip fractures. Most observed fractures were nonhip-nonvertebral, in accordance with a recent publication naming them "the neglected fractures" (27) , as well as a previous study assessing their burden (28) . As with most other country-specific FRAX algorithms, the model construction for Israel did not include local data on nonhip fractures. In contrast with hip fractures, the incidence of other (less fatal) major fractures is usually not recorded on a national level. The ratio between rates of hip fracture and nonhip fracture was imputed from Malmö, Sweden, data (8) . While the overall lifetime risk of a MOF in Israel is comparable to the average of the Western world (29), the incidence observed in this study may suggest a larger proportion of nonhip fractures as compared with Sweden. This finding agrees with a recent study from the Netherlands (30) , indicating that some recalibration may be beneficial for prediction of nonhip fractures. In the Os des Femmes de Lyon (OFELY) Study, Sornay-Rendu et al. (31) also reported higher observed fracture incidence as compared with FRAX predictions. The observed asymmetry in FRAX's discriminative ability in favor of hip fracture as compared with MOF conforms with the large study led by Hippisley-Cox and Coupland (18) in England. Their findings indicated better overall calibration, which might have stemmed from their substantially younger study population (median age, 47 years), who had not reached peak fracture incidence within 10 years of follow-up. In general, some variation in fracture incidence rates may be attributed to technical artifacts such as nonuniform event documentation, leading to a seemingly heterogeneous risk (7) , even between countries with similar environmental exposure and genetic composition. It can be argued that use of a retrospective database may have underestimated the true FRAX scores due to EMRs' nature of supporting only passive collection of risk factor data. However, the conformity of our findings to those of prospective studies with self-reported questionnaires (32) suggests that a computerized EMR database can provide a sufficiently reliable capture of a person's risk profile and may thus be a reasonable candidate for automatic risk calculation. The current study suggests that while imperfect, an EMR-derived estimate which combines several well-established fracture risk markers still outperforms the currently used "densicentricity" approach employing T-scores only and can produce actionable recommendations. Moreover, the current availability of the FRAX calculator as a stand-alone Web page may pose a barrier to its widespread use. Just as important as prediction is how the predictions are integrated with routine clinical systems (33) , and offline calculation based on readily available electronic data could dramatically improve the implementation and clinical utility of a multivariate tool in daily use. In our era of brief visits to the general physician's clinic, "recycling" already-existing health records can save time and support medical decision-making or can trigger automatic alerts when a predefined intervention threshold is exceeded. In future studies, researchers can focus on selecting such thresholds and evaluate their impact on fracture detection rates.
This study was limited primarily by a lack of information on parental history of hip fracture, a substantial risk factor (34) , data on which is not routinely collected in the usual care setting. Assuming relative risks of 1.75 and 1.38 for hip fracture and MOF, respectively (34) , and 10% misdetection, our overall estimate of expected fracture rates in the total population may be slightly underestimated, by approximately 0.2% for hip fractures and 0.3% for MOFs. Incorporating patientreported information on family history through a secured structured Web interface (portal) may be an efficient method of improving the quality of these data while saving time on physician encounters. Alternatively, the physician can be presented with a risk interval, where the upper and lower estimates are based on the assumptions of yes/no for parental hip fracture, respectively. Some underreporting is also anticipated with alcohol exposure. It is notable that Israel is known for its low alcohol consumption (35) (rated as one of the lowest among countries in the Organisation for Economic Co-operation and Development), and the weight of this risk factor (and consequently the magnitude of potential bias) is smaller than that of parental history. The scope of this study was not to develop a new tool but rather to appraise and externally validate the currently available and commonly used international decision support tool, on the way to potentially adopting it in local guidelines. The similar performance observed when deriving a parsimonious model based on age and BMD may be due to low prevalence reflected in the low attributable risk of the remaining risk factors, which affects their discriminatory ability at the population level.
In summary, this study confirms the appropriateness of FRAX for fracture risk stratification. Integration with routine clinical systems is key in implementing such a multivariate tool and enhancing its utilization in daily practice.
